{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T13:31:27Z","timestamp":1782826287859,"version":"3.54.5"},"reference-count":63,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1053\/j.ajkd.2008.11.021","type":"journal-article","created":{"date-parts":[[2009,1,22]],"date-time":"2009-01-22T04:17:03Z","timestamp":1232597823000},"page":"332-345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Dual Blockade of the Renin-Angiotensin System for Cardiorenal Protection: An Update"],"prefix":"10.1053","volume":"53","author":[{"given":"Mustafa","family":"Ar\u0131c\u0131","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunus","family":"Erdem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2008.11.021_bib1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2796.2008.01981.x","article-title":"Renin-angiotensin system revisited","volume":"264","author":"Fyhrquist","year":"2008","journal-title":"J Intern Med"},{"key":"10.1053\/j.ajkd.2008.11.021_bib2","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/0002-9149(82)90348-4","article-title":"Development and design of specific inhibitors of angiotensin-converting enzyme","volume":"49","author":"Cushman","year":"1982","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.ajkd.2008.11.021_bib3","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1517\/17460441.1.6.609","article-title":"How the antihypertensive losartan was discovered","volume":"1","author":"Bhardwaj","year":"2006","journal-title":"Expert Opin Drug Discov"},{"key":"10.1053\/j.ajkd.2008.11.021_bib4","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/ndt\/16.5.885","article-title":"Modulation of the renin-angiotensin system in proteinuric renal disease: are there added benefits?","volume":"16","author":"Lewington","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2008.11.021_bib5","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1523-1755.2005.00145.x","article-title":"Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications","volume":"67","author":"Wolf","year":"2005","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2008.11.021_bib6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.7326\/0003-4819-148-1-200801010-00189","article-title":"Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension","volume":"148","author":"Matchar","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ajkd.2008.11.021_bib7","doi-asserted-by":"crossref","first-page":"45J","DOI":"10.1016\/j.amjcard.2007.05.014","article-title":"New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers","volume":"100","author":"Weber","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.ajkd.2008.11.021_bib8","doi-asserted-by":"crossref","first-page":"25J","DOI":"10.1016\/j.amjcard.2007.05.011","article-title":"Rationale for double renin-angiotensin-aldosterone-system blockade","volume":"100","author":"Unger","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.ajkd.2008.11.021_bib9","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/ajh.2007.56","article-title":"Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy","volume":"23","author":"Cohn","year":"2008","journal-title":"Am J Hypertens"},{"key":"10.1053\/j.ajkd.2008.11.021_bib10","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1093\/eurheartj\/ehi454","article-title":"Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?","volume":"26","author":"van de Wal","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1053\/j.ajkd.2008.11.021_bib11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2005.02.016","article-title":"Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition","volume":"106","author":"van de Wal","year":"2006","journal-title":"Int J Cardiol"},{"key":"10.1053\/j.ajkd.2008.11.021_bib12","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1097\/01.ASN.0000071512.93927.4E","article-title":"Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease","volume":"14","author":"Huang","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2008.11.021_bib13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00041552-200501000-00011","article-title":"Update on the role of the AT2 receptor","volume":"4","author":"Carey","year":"2005","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1053\/j.ajkd.2008.11.021_bib14","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(99)10365-9","article-title":"Angiotensin II receptor antagonists","volume":"355","author":"Burnier","year":"2000","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2008.11.021_bib15","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/01.HYP.0000161880.59963.da","article-title":"Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension","volume":"45","author":"Doulton","year":"2005","journal-title":"Hypertension"},{"key":"10.1053\/j.ajkd.2008.11.021_bib16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3317\/jraas.2004.012","article-title":"Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria","volume":"5","author":"Morgan","year":"2004","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1053\/j.ajkd.2008.11.021_bib17","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","year":"2008","journal-title":"New Engl J Med"},{"key":"10.1053\/j.ajkd.2008.11.021_bib18","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","article-title":"2007 Guidelines for the management of arterial hypertension","volume":"25","year":"2007","journal-title":"J Hypertens"},{"key":"10.1053\/j.ajkd.2008.11.021_bib19","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"365","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2008.11.021_bib20","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2008.11.021_bib21","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"New Engl J Med"},{"key":"10.1053\/j.ajkd.2008.11.021_bib22","doi-asserted-by":"crossref","first-page":"1090.e1","DOI":"10.1016\/j.amjmed.2007.02.029","article-title":"Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy","volume":"120","author":"Jneid","year":"2007","journal-title":"Am J Med"},{"key":"10.1053\/j.ajkd.2008.11.021_bib23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cardfail.2007.11.008","volume":"14","author":"Lakhdar","year":"2008","journal-title":"J Card Fail"},{"key":"10.1053\/j.ajkd.2008.11.021_bib24","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00392-008-0668-3","article-title":"RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection","volume":"97","author":"Werner","year":"2008","journal-title":"Clin Res Cardiol"},{"key":"10.1053\/j.ajkd.2008.11.021_bib25","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2008.11.021_bib26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0140-6736(08)61212-X","article-title":"Renin-angiotensin blockade and kidney disease","volume":"372","author":"Sarafidis","year":"2008","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2008.11.021_bib27","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000112269","article-title":"Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease","volume":"28","author":"Toto","year":"2008","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ajkd.2008.11.021_bib28","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","article-title":"Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study","volume":"321","author":"Mogensen","year":"2000","journal-title":"BMJ"},{"key":"10.1053\/j.ajkd.2008.11.021_bib29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2337\/diacare.28.2.273","article-title":"Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes","volume":"28","author":"Andersen","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ajkd.2008.11.021_bib30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","article-title":"Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial","volume":"361","author":"Nakao","year":"2003","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2008.11.021_bib31","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1159\/000098196","article-title":"Controversy about COOPERATE ABPM trial data","volume":"26","author":"Bidani","year":"2006","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ajkd.2008.11.021_bib32","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(08)60681-9","article-title":"The COOPERATE trial: a letter of concern","volume":"371","author":"Kunz","year":"2008","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2008.11.021_bib33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.ajkd.2006.04.077","article-title":"Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data","volume":"48","author":"MacKinnon","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2008.11.021_bib34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","article-title":"Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease","volume":"148","author":"Kunz","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ajkd.2008.11.021_bib35","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1053\/j.ajkd.2008.03.008","article-title":"Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression","volume":"52","author":"Catapano","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2008.11.021_bib36","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-148-1-200801010-00191","article-title":"Inhibitors of the renin-angiotensin system: Proven benefits, unproven safety","volume":"148","author":"Parfrey","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ajkd.2008.11.021_bib37","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.ki.5002455","article-title":"Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial","volume":"72","author":"Bakris","year":"2007","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2008.11.021_bib38","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1097\/HJH.0b013e32830508aa","article-title":"Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial","volume":"26","author":"Menne","year":"2008","journal-title":"J Hypertens"},{"key":"10.1053\/j.ajkd.2008.11.021_bib39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/01.HYP.0000047512.58862.A9","article-title":"Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor?","volume":"41","author":"Forclaz","year":"2003","journal-title":"Hypertension"},{"key":"10.1053\/j.ajkd.2008.11.021_bib40","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/ndt\/gfn239","article-title":"Maximizing inhibition of the renin-angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers","volume":"23","author":"Berl","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2008.11.021_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccl.2007.12.001","article-title":"Role and optimal dosing of angiotensin-converting enzyme inhibitors in heart failure","volume":"26","author":"Kazi","year":"2008","journal-title":"Cardiol Clin"},{"key":"10.1053\/j.ajkd.2008.11.021_bib43","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/01.mnh.0000165889.60254.98","article-title":"Aldosterone and end-organ damage","volume":"14","author":"Brown","year":"2005","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1053\/j.ajkd.2008.11.021_bib44","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2008.11.021_bib45","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2008.11.021_bib46","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1681\/ASN.2007101079","article-title":"The aggravating mechanisms of aldosterone on kidney fibrosis","volume":"19","author":"Remuzzi","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2008.11.021_bib47","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlin","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2008.11.021_bib48","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(06)69442-7","article-title":"Oral renin inhibitors","volume":"368","author":"Staessen","year":"2006","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2008.11.021_bib49","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3317\/jraas.2007.028","article-title":"Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension","volume":"8","author":"Uresin","year":"2007","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1053\/j.ajkd.2008.11.021_bib50","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","article-title":"Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial","volume":"370","author":"Oparil","year":"2007","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2008.11.021_bib51","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2008.11.021_bib52","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0140-6736(07)61099-X","article-title":"Dual inhibition of the renin system by aliskiren and valsartan","volume":"370","author":"Birkenhager","year":"2007","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2008.11.021_bib53","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMe0803375","article-title":"Aliskiren and dual therapy in type 2 diabetes mellitus","volume":"358","author":"Ingelfinger","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2008.11.021_bib54","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/MNH.0b013e32830baa9b","article-title":"Renin inhibition: should it supplant ACE inhibitors and ARBs in high risk patients?","volume":"17","author":"Gaddam","year":"2008","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1053\/j.ajkd.2008.11.021_bib55","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/00004872-200018080-00020","article-title":"Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients","volume":"18","author":"Azizi","year":"2000","journal-title":"Hypertens"},{"key":"10.1053\/j.ajkd.2008.11.021_bib56","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/00005344-200006000-00017","article-title":"Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension","volume":"35","author":"Stergiou","year":"2000","journal-title":"Cardiovasc Pharmacol"},{"key":"10.1053\/j.ajkd.2008.11.021_bib57","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0895-7061(01)01296-1","article-title":"Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake","volume":"14","author":"Weir","year":"2001","journal-title":"Am J Hypertens"},{"key":"10.1053\/j.ajkd.2008.11.021_bib58","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0895-7061(00)01304-2","article-title":"Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial","volume":"14","author":"Weir","year":"2001","journal-title":"Am J Hypertens"},{"key":"10.1053\/j.ajkd.2008.11.021_bib59","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00228-005-0931-8","article-title":"Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension","volume":"61","author":"Anan","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2008.11.021_bib60","doi-asserted-by":"crossref","first-page":"39A","DOI":"10.1177\/14732300050330S106","article-title":"Ventricular and vascular remodeling effects of the angiotensin II receptor blocker telmisartan and\/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients","volume":"33","author":"Petrovic","year":"2005","journal-title":"J Int Med Res"},{"key":"10.1053\/j.ajkd.2008.11.021_bib61","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2008.11.021_bib62","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1161\/01.CIR.99.20.2658","article-title":"Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure","volume":"99","author":"Baruch","year":"1999","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2008.11.021_bib63","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1161\/01.CIR.99.8.990","article-title":"Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure","volume":"99","author":"Hamroff","year":"1999","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2008.11.021_bib64","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1067\/mhj.2001.114802","article-title":"ADEPT: addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects","volume":"141","author":"Murdoch","year":"2001","journal-title":"Am Heart J"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638608017502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638608017502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:50:55Z","timestamp":1759456255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638608017502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S0272638608017502"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2008.11.021","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual Blockade of the Renin-Angiotensin System for Cardiorenal Protection: An Update","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2008.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}